RARS1 and nasopharyngeal carcinoma: Yet another effect of RARS on cancers involves gene fusion between RARS and mitotic arrest deficient 1-like protein 1 (MAD1L1), which induces the proliferation of nasopharyngeal cancer cell lines and their chemo- and radio-resistance (Zhong et al., 2018).